Compare Cassava Sciences Inc (FLNA) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Nucor Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Nucor Corporation trades at $236.94 (market cap $53.94B). The key difference: Nucor Corporation is far larger — about 1015.1× Cassava Sciences Inc's market cap, and Nucor Corporation pays a 0.95% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NUE | |
|---|---|---|
Market Cap | $53.14M | $53.94B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $266.35 |
52-Week Low | $1.09 | $131.78 |
Enterprise Value | -$33.43M | $58.59B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Nucor (NUE) trades at $234.16, up 0.5% on the day, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 2026, and the company maintains a solid balance sheet with a 53-year dividend growth streak. Revenue trends show recovery from 2024 lows, supported by higher steel prices and expansion projects.
Outlook remains positive with a consensus price target of $262.89, though risks include cyclical demand and margin pressures. The stock offers value with a P/E of 23.5 and robust cash flow, but investors should monitor Q2 2026 earnings due soon for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
